Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation

Khanolkar, M. , Morris, R. H. K. , Thomas, A. W. , Bolusani, H. , Roberts, A. W. , Green, J. , Jackson, S. K. and Evans, L. M. (2008) Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation. Atherosclerosis, 197 (2). pp. 718-724. ISSN 0021-9150

Full text not available from this repository

Publisher's URL: http://dx.doi.org/10.1016/j.atherosclerosis.2007.0...


Item Type:Article
Uncontrolled Keywords:type 2 diabetes mellitus, rosiglitazone, platelets
Faculty/Department:~Pre-2010 Faculty Structure > Health and Life Sciences > School of Life Sciences
~Pre-2012 Faculty Structure > Faculty of Health and Life Sciences
Faculty of Health and Life Sciences
ID Code:7138
Deposited By: H. Hammond
Deposited On:16 Jul 2010 08:02
Last Modified:22 Nov 2012 15:36

Repository Staff Only: item control page
Copyright 2013 © UWE better together